ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Cypherpunk Technologies Inc.
0.7131
+0.0084
1.19%
盤前：
0.7500
0.0369
+5.17%
06:03 EDT
成交量：
120.19萬
成交額：
88.20萬
市值：
6,416.45萬
市盈率：
10.19
高：
0.7599
開：
0.7200
低：
0.7038
收：
0.7047
52周最高：
3.70
52周最低：
0.2223
股本：
8,997.96萬
流通股本：
7,419.73萬
量比：
0.42
換手率：
1.62%
股息：
- -
股息率：
- -
每股收益(TTM):
0.0700
每股收益(LYR):
0.0700
淨資產收益率：
5.11%
總資產收益率：
-21.61%
市淨率：
0.42
市盈率(LYR):
10.19
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字：
Cypherpunk Technologies Inc.
交易所：
NASDAQ
成立時間：
2011
員工人數：
52
公司地址：
47 Thorndike Street,Suite B1-1,Cambridge,Massachusetts,United States
官網：
http://www.leaptx.com;www.cypherpunk.com
郵編：
02141
電話：
617 714 0360
傳真：
- -
簡介：
Cypherpunk Technologies Inc.最初作為Dekkun Corporation成立於2011年1月3日，是一家特拉華州公司。2025年11月13日，公司更名為Cypherpunk Technologies Inc.。該公司是一家開發新型生物標誌物靶向抗體療法的生物製藥公司，旨在通過抑制基本的腫瘤促進途徑、靶向癌症特異性細胞表面分子和利用免疫系統攻擊癌細胞來治療癌症患者。他們的策略是識別、獲取和開發分子，這些分子將迅速轉化為高影響的治療方法，產生持久的臨床效益並提高患者的預后。他們的主要臨床階段項目是DKN-01，一種抑制dickkopf相關蛋白1(“DKK1”)的單克隆抗體。他們目前正在多個正在進行的臨床試驗中研究DKN-01在食管胃癌、婦科癌症或結直腸癌患者中的應用。他們的第二個臨床階段項目是FL-301，這是一種針對細胞表面表達Claudin18.2的細胞的單克隆抗體。他們還有兩個臨床前抗體項目，FL-302和FL-501。
董事
名稱
職位
Douglas E. Onsi
Director,Chief Executive Officer and President
Khing Oei
Director and Non-Executive Chairman
Thomas Dietz
Lead Independent Director
William McEvoy
Director and Chief Investment Officer
Christian Richard
Director
Christopher K. Mirabelli
Director
James Cavanaugh
Director
Joseph Loscalzo
Director
Nissim Mashiach
Director
Patricia Martin
Director
Richard Schilsky
Director
William Li
Director
股東
名稱
職位
Douglas E. Onsi
Director,Chief Executive Officer and President
Christine Granfield
Vice President, Head of Regulatory Affairs and Quality
Jason Baum
Chief Scientific Officer
Mark O'Mahony
Chief Manufacturing Officer
William McEvoy
Director and Chief Investment Officer
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CYPH/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CYPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYPH\",,,,,undefined,":{"symbol":"CYPH","market":"US","secType":"STK","nameCN":"Cypherpunk Technologies Inc.","latestPrice":0.7131,"timestamp":1774296000000,"preClose":0.7047,"halted":0,"volume":1201879,"hourTrading":{"tag":"盘前","latestPrice":0.75,"preClose":0.7131,"latestTime":"06:03 EDT","volume":14326,"amount":10743.4506205,"timestamp":1774346595170,"change":0.0369,"changeRate":0.051746,"amplitude":0.014023},"delay":0,"changeRate":0.011919965942954396,"floatShares":74197300,"shares":89979619,"eps":0.069999,"marketStatus":"盤前交易","change":0.0084,"latestTime":"03-24 06:24:30 EDT","open":0.72,"high":0.7599,"low":0.7038,"amount":882037.9652175,"amplitude":0.079608,"askPrice":0.8085,"askSize":96,"bidPrice":0.7175,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.069999,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774359000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.7131,"preHourTrading":{"tag":"盘前","latestPrice":0.75,"preClose":0.7131,"latestTime":"06:03 EDT","volume":14326,"amount":10743.4506205,"timestamp":1774346595170,"change":0.0369,"changeRate":0.051746,"amplitude":0.014023},"postHourTrading":{"tag":"盘后","latestPrice":0.7179,"preClose":0.7131,"latestTime":"19:59 EDT","volume":5601,"amount":4008.3998,"timestamp":1774310346915,"change":0.0048,"changeRate":0.006731,"amplitude":0.024541},"volumeRatio":0.4234804137383695,"impliedVol":2.1525,"impliedVolPercentile":0.6477},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYPH\",,,,,undefined,":{"symbol":"CYPH","floatShares":74197300,"roa":"-21.61%","roe":"5.11%","lyrEps":0.069999,"volumeRatio":0.4234804137383695,"shares":89979619,"dividePrice":0,"high":0.7599,"amplitude":0.079608,"preClose":0.7047,"low":0.7038,"week52Low":0.2223,"pbRate":"0.42","week52High":3.6999,"institutionHeld":0,"latestPrice":0.7131,"committee":0.020408,"eps":0.069999,"divideRate":0,"volume":1201879,"delay":0,"ttmEps":0.069999,"open":0.72,"prevYearClose":1.16,"prevWeekClose":0.7047,"prevMonthClose":0.6241,"prevQuarterClose":1.16,"fiveDayClose":0.7049,"twentyDayClose":0.6465,"sixtyDayClose":1.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-16","symbol":"CYPH","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2025-11-12","symbol":"CYPH","fiscalQuarterEnding":"2025/09","expectedEps":-0.24,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2025-08-14","symbol":"CYPH","fiscalQuarterEnding":"2025/06","expectedEps":-0.29,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.4},{"market":"US","date":"2025-05-13","symbol":"CYPH","fiscalQuarterEnding":"2025/03","expectedEps":-0.38,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2025-03-26","symbol":"CYPH","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"盤前","type":"earning","dateTimestamp":1742961600000,"reportTimeType":"pre","actualEps":-0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYPH\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CYPH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CYPH","date":"2026-03-23","current":10.187288,"percent":0.976471,"low":-3.311343,"twenty":-1.415962,"median":-1.035045,"eighty":-0.705416,"high":13.381249,"avg":-0.584479,"sd":2.924633,"marketCap":63408637},"quantilePoints":[{"date":"2025-11-21","current":-3.277895,"twenty":-3.284585,"median":-3.277895,"eighty":-2.994703,"marketCap":166556409},{"date":"2025-11-28","current":-1.705843,"twenty":-3.277895,"median":-2.709281,"eighty":-1.906531,"marketCap":86677315},{"date":"2025-12-05","current":-1.415962,"twenty":-3.150793,"median":-1.873083,"eighty":-1.44272,"marketCap":71947836},{"date":"2025-12-12","current":-1.76159,"twenty":-2.851992,"median":-1.705843,"eighty":-1.398123,"marketCap":89509907},{"date":"2025-12-19","current":-1.042571,"twenty":-2.608937,"median":-1.627798,"eighty":-1.324537,"marketCap":52975135},{"date":"2025-12-26","current":-1.304468,"twenty":-2.341354,"median":-1.53303,"eighty":-1.304468,"marketCap":66282652},{"date":"2026-01-02","current":-1.293319,"twenty":-1.993496,"median":-1.454984,"eighty":-1.304468,"marketCap":65716134},{"date":"2026-01-09","current":-1.293319,"twenty":-1.797268,"median":-1.371364,"eighty":-1.293319,"marketCap":65716134},{"date":"2026-01-16","current":-1.226423,"twenty":-1.750441,"median":-1.337916,"eighty":-1.242033,"marketCap":62317024},{"date":"2026-01-23","current":-1.013249,"twenty":-1.705843,"median":-1.321192,"eighty":-1.226423,"marketCap":51485192},{"date":"2026-01-30","current":-0.778667,"twenty":-1.705843,"median":-1.304468,"eighty":-1.159528,"marketCap":39565645},{"date":"2026-02-06","current":-0.678547,"twenty":-1.650097,"median":-1.293319,"eighty":-1.020273,"marketCap":34478309},{"date":"2026-02-13","current":-0.668289,"twenty":-1.6055,"median":-1.271021,"eighty":-0.919706,"marketCap":33957112},{"date":"2026-02-20","current":-0.745777,"twenty":-1.6055,"median":-1.259871,"eighty":-0.827412,"marketCap":37894415},{"date":"2026-02-27","current":-0.777775,"twenty":-1.489547,"median":-1.231998,"eighty":-0.783751,"marketCap":39520323},{"date":"2026-03-06","current":-0.686686,"twenty":-1.460559,"median":-1.226423,"eighty":-0.771844,"marketCap":34891868},{"date":"2026-03-13","current":-0.672303,"twenty":-1.451639,"median":-1.170677,"eighty":-0.741719,"marketCap":34161059},{"date":"2026-03-20","current":13.207709,"twenty":-1.422651,"median":-1.042571,"eighty":-0.709787,"marketCap":63687574},{"date":"2026-03-23","current":13.149863,"twenty":-1.415962,"median":-1.035045,"eighty":-0.705416,"marketCap":63408637}],"updateTime":1774347870902},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":118044172,"yearFounded":2011,"employeeNum":52,"address":"47 Thorndike Street,Suite B1-1,Cambridge,Massachusetts,United States","zipCode":"02141","officePhone":"617 714 0360"},"stockCompanyDetail":{"websiteUrl":"http://www.leaptx.com;www.cypherpunk.com","stockEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0648},{"period":"3month","weight":-0.3957},{"period":"6month","weight":1.3205},{"period":"1year","weight":0.7783},{"period":"ytd","weight":-0.3853}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Cypherpunk Technologies Inc.最初作為Dekkun Corporation成立於2011年1月3日，是一家特拉華州公司。2025年11月13日，公司更名為Cypherpunk Technologies Inc.。該公司是一家開發新型生物標誌物靶向抗體療法的生物製藥公司，旨在通過抑制基本的腫瘤促進途徑、靶向癌症特異性細胞表面分子和利用免疫系統攻擊癌細胞來治療癌症患者。他們的策略是識別、獲取和開發分子，這些分子將迅速轉化為高影響的治療方法，產生持久的臨床效益並提高患者的預后。他們的主要臨床階段項目是DKN-01，一種抑制dickkopf相關蛋白1(“DKK1”)的單克隆抗體。他們目前正在多個正在進行的臨床試驗中研究DKN-01在食管胃癌、婦科癌症或結直腸癌患者中的應用。他們的第二個臨床階段項目是FL-301，這是一種針對細胞表面表達Claudin18.2的細胞的單克隆抗體。他們還有兩個臨床前抗體項目，FL-302和FL-501。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.063985},{"month":2,"riseRate":0.3,"avgChangeRate":-0.035965},{"month":3,"riseRate":0.4,"avgChangeRate":-0.055851},{"month":4,"riseRate":0.444444,"avgChangeRate":0.024066},{"month":5,"riseRate":0.333333,"avgChangeRate":0.10817},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.10012},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.017339},{"month":8,"riseRate":0.333333,"avgChangeRate":0.008005},{"month":9,"riseRate":0.444444,"avgChangeRate":0.109211},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.026459},{"month":11,"riseRate":0.333333,"avgChangeRate":0.194397},{"month":12,"riseRate":0.444444,"avgChangeRate":0.113236}],"exchange":"NASDAQ","name":"Cypherpunk Technologies Inc.","nameEN":"Cypherpunk Technologies Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CYPH\",market:\"US\",,,undefined,":{"directors":[{"name":"Douglas E. Onsi","position":"Director,Chief Executive Officer and President"},{"name":"Khing Oei","position":"Director and Non-Executive Chairman"},{"name":"Thomas Dietz","position":"Lead Independent Director"},{"name":"William McEvoy","position":"Director and Chief Investment Officer"},{"name":"Christian Richard","position":"Director"},{"name":"Christopher K. Mirabelli","position":"Director"},{"name":"James Cavanaugh","position":"Director"},{"name":"Joseph Loscalzo","position":"Director"},{"name":"Nissim Mashiach","position":"Director"},{"name":"Patricia Martin","position":"Director"},{"name":"Richard Schilsky","position":"Director"},{"name":"William Li","position":"Director"}],"executives":[{"name":"Douglas E. Onsi","position":"Director,Chief Executive Officer and President"},{"name":"Christine Granfield","position":"Vice President, Head of Regulatory Affairs and Quality"},{"name":"Jason Baum","position":"Chief Scientific Officer"},{"name":"Mark O'Mahony","position":"Chief Manufacturing Officer"},{"name":"William McEvoy","position":"Director and Chief Investment Officer"}]}}}